Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sonnet BioTherapeutics Holdings, Inc. (SONN)

1.16   0.05 (4.5%) 01-27 16:00
Open: 1.1 Pre. Close: 1.11
High: 1.17 Low: 1.1
Volume: 114,380 Market Cap: 9(M)

Technical analysis

as of: 2023-01-27 4:48:06 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.63     One year: 1.96
Support: Support1: 0.93    Support2: 0.78
Resistance: Resistance1: 1.39    Resistance2: 1.67
Pivot: 1.25
Moving Average: MA(5): 1.13     MA(20): 1.23
MA(100): 1.42     MA(250): 3.02
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 15.6     %D(3): 15.7
RSI: RSI(14): 47.7
52-week: High: 9.38  Low: 0.23
Average Vol(K): 3-Month: 3,072 (K)  10-Days: 226 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SONN ] has closed above bottom band by 29.1%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.17 - 1.18 1.18 - 1.18
Low: 1.08 - 1.09 1.09 - 1.1
Close: 1.15 - 1.16 1.16 - 1.17

Company Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Headline News

Sat, 28 Jan 2023
All you need to know about Zack Tinker's role on Fire Country ... - NewsBreak Original

Sat, 28 Jan 2023
Greedy, selfish, rich jerks - Freethought Blogs –

Thu, 26 Jan 2023
Goodpasture athletic trainer Chris Snoddy remembered as 'one of a ... - Main Street Preps

Wed, 25 Jan 2023
Seniors seize their chance to write and direct, one scheme at a time - The Sagamore

Tue, 24 Jan 2023
Byzantine tax laws help rich people — like the Getty family — shield ... - KCRW

Thu, 19 Jan 2023
$SONN Sonnet Biotherapeutics Holdings Inc Files For Common ... - CML News

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 8 (M)
% Held by Insiders 6.2e+006 (%)
% Held by Institutions 2.1 (%)
Shares Short 322 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.966e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -8
Return on Assets (ttm) 478.3
Return on Equity (ttm) -106.5
Qtrly Rev. Growth 349940
Gross Profit (p.s.) -147.46
Sales Per Share -510.89
EBITDA (p.s.) -3.57458e+007
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -28 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -1.49

Stock Dividends

Dividend 0
Forward Dividend 14270
Dividend Yield 0%
Dividend Pay Date 2020-04-01
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.